Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.

Details

Serval ID
serval:BIB_2471EDE29414
Type
Article: article from journal or magazin.
Collection
Publications
Title
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.
Journal
Annals of oncology
Author(s)
Berthold D.R., Pond G.R., de Wit R., Eisenberger M., Tannock I.F.
Working group(s)
TAX 327 Investigators
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Publication state
Published
Issued date
10/2008
Peer-reviewed
Oui
Volume
19
Number
10
Pages
1749-1753
Language
english
Notes
Publication types: Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
The TAX 327 study compared 3-weekly docetaxel, weekly docetaxel or 3-weekly mitoxantrone, each with prednisone, for 1006 patients with metastatic hormone-refractory prostate cancer. Survival and symptom control were superior following 3-weekly docetaxel as compared with mitoxantrone. At progression, many patients were treated with the other drug. Here, we provide a retrospective report of survival and prostate-specific antigen (PSA) response after second-line therapy.
The TAX 327 database provided information about treatment after progression on first-line therapy, and survival has been updated. Investigators were asked to provide information about crossover treatment and serial PSA values.
We identified 232 crossover patients. Median survival after crossover was 10 months and did not depend on direction of crossover. Data on PSA response are available for 96 patients: PSA response (> or =50% reduction) occurred in 15% of 71 men receiving mitoxantrone after docetaxel and in 28% of 25 men receiving docetaxel after mitoxantrone. Median PSA progression-free survival was 3.4 months for mitoxantrone after docetaxel and 5.9 months for docetaxel after mitoxantrone.
One quarter of men received crossover therapy and survival was similar in the crossover groups. The PSA response rate to docetaxel after mitoxantrone was higher than that for mitoxantrone after docetaxel.

Keywords
Aged, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Cross-Over Studies, Drug Administration Schedule, Humans, Male, Mitoxantrone/administration & dosage, Prednisone/administration & dosage, Prostate-Specific Antigen/blood, Prostatic Neoplasms/blood, Prostatic Neoplasms/drug therapy, Retrospective Studies, Survival Rate, Taxoids/administration & dosage
Pubmed
Open Access
Yes
Create date
30/11/2016 23:17
Last modification date
20/08/2019 13:02
Usage data